Meitheal Pharmaceuticals, Inc.

Thank you to everyone who joined Meitheal Pharmaceuticals and the Biosimilars Forum in supporting #GlobalBiosimilarsWeek. Together, we’re working to make #biosimilars accessible to the patients who need them. Stay up to date on the biosimilars industry by following the Biosimilars Forum: https://lnkd.in/g_9eUB4h #GlobalBiosimilarsWeek #BiosimilarAccess

During #GlobalBiosimilarsWeek, Meitheal reaffirms its commitment to simplifying access to life-changing medicine, for good. Greater access to #biosimilars means lower costs for patients.   Follow the Biosimilars Forum to stay up to date on the biosimilars industry: https://lnkd.in/gmk3k9vM #GlobalBiosimilarsWeek #BiosimilarAccess

Join Meitheal Pharmaceuticals and The Biosimilars Forum in supporting #GlobalBiosimilarsWeek. The Biosimilars Forum and its members are committed to helping American patients by increasing access to lower-cost biosimilars. At Meitheal, we work every day to advance our company's central mission: to simplify access to life-changing medicine, for good.  

"We are excited to introduce Ropivacaine Hydrochloride Injection, USP, which will provide healthcare providers with a trusted alternative for local anesthesia," stated Brett Novak, Senior Vice President of Commercial Operations. "At Meitheal, we are committed to supporting patient care by ensuring a reliable supply of high-quality, essential medications. The addition of Ropivacaine to our product offerings reinforces our dedication to sustainable healthcare solutions across the United States."   Ropivacaine Hydrochloride Injection, USP serves as a dependable choice for local anesthesia, reflecting Meitheal's ongoing mission to empower healthcare providers and enhance patient outcomes.   Learn more about Ropivacaine Hydrochloride Injection, USP here: https://lnkd.in/gAAd7Awr   Think sustainability, think Meitheal.

Palm Springs, with its stunning landscapes and rich architectural heritage, has become a gathering place for pioneers in healthcare. We’re excited to experience all Palm Springs has to offer at the upcoming California Society of Health-System Pharmacists 2024 seminar "Inspiring Innovation: Leading the Change." Meitheal is committed to advancing the future of healthcare by stabilizing the Generics market, expanding into Biologics and Biosimilars, and simplifying access to life-changing medicines for the common good. We look forward to connecting with healthcare leaders and sharing our vision for transforming patient care at this year's seminar. Think sustainability, think Meitheal. #PalmSprings #Generics #Biologics #Biosimilars

BREAKING NEWS: Meitheal Pharmaceuticals, Inc., a fully integrated biopharmaceutical company based in Chicago, Illinois, secures exclusive commercial licensing agreement in U.S. for three biosimilars. Meitheal is thrilled to announce a major expansion of its biosimilar portfolio through a recent exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. Through this collaboration, Meitheal will market and distribute in the United States three essential biosimilars in two different therapeutic fields – pegfilgrastim and filgrastim for use in oncology, and follitropin alpha for use in fertility. These biosimilars will increase Meitheal’s biosimilar portfolio to contain eight different treatments, and will help Meitheal address key patient needs by providing more affordable, accessible treatment options in the United States. As Meitheal’s CEO, Tom Shea, explains, “This expansion furthers our commitment to delivering cost-saving innovation to patients and the broader healthcare system.” Meitheal’s parent company and its affiliates have invested over $300 million in capital and R&D in recent years to support sustainable product supply, including investing $30 million in a monoclonal antibody drug substance facility. Learn more about what is on the horizon at Meitheal in today’s news release: https://lnkd.in/gXh2pP6N Think sustainability, think Meitheal. #Biosimilars #HealthcareInnovation #PatientAccess #MeithealPharma #Biopharma

Let us be a part of your story! Meitheal Fertility is onsite at the ASRM conference in Denver this week. Stop by booth 4521, grab a seat, and let’s have a conversation about the fertility journey. Whether you're providing help or seeking support yourself, we’re here for you, because we believe that growing a family takes a village.

GRx + Biosims: Generics & Biosimilars Conference North Bethesda, MD | October 21-23 Bethesda North Mariott Hotel & Conference Center North Bethesda, known for its thriving healthcare and biotech sector, is the ideal location for this year’s GRx+Biosims Generics & Biosimilars Conference. We’re excited to join industry leaders to explore the latest innovations in generics and biosimilars and discuss how we can further expand access to affordable, life-saving medicines. At Meitheal, we are committed to advancing the development and distribution of high-quality generics and biosimilars, improving sustainability, and ensuring patients have access to essential treatments. We look forward to sharing our progress and connecting with like-minded innovators. Think sustainability. Think Meitheal. #Generics #Biosimilars #Biologics